Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2014

At a glance

  • Drugs Erlotinib (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 29 May 2014 Trial status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 19 Jul 2013 Planned end date changed from 1 Aug 2012 to 1 Mar 2016 as reported by ClinicalTrials.gov.
    • 19 Jul 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top